Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Condition: Heart Failure With Normal Ejection Fraction Interventions: Dietary Supplement: Active lozenge; Drug: Placebo Sponsors: Penobscot Bay Medical Center; HumanN Completed
Condition: Arthropathy of Hip Interventions: Drug: Vecuronium 0.1 mg/kg; Drug: Vecuronium 0.2mg/kg Sponsors: Craig Curry; Maine Medical Center; Spectrum Medical Group Anesthesiology Completed
Condition: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy Intervention: Drug: Cenobamate Sponsor: SK Life Science, Inc. Enrolling by invitation
Conditions: Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Palbociclib; Drug: Letrozole; Drug: Fulvestrant; Other: Questionnaire Administration; Other: Quality-of-Life Assessment Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Condition: Colorectal Cancer Screening Interventions: Behavioral: Notification; Behavioral: Training Sponsors: Massachusetts General Hospital; Maine Medical Center; Brigham and Women's Hospital; Newton-Wellesley Hospital; North Shore Medical Center Enrolling by invitation
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Condition: Breast Cancer Interventions: Radiation: Radiation; Other: No Radiation Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group Recruiting
Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Entinostat; Drug: Exemestane; Drug: Goserelin; Drug: Goserelin Acetate; Other: Placebo Administration; Other: Quality-of-Life Assessment Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Suspended
Conditions: Ductal Breast Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Drug: Systemic Chemotherapy; Drug: Tamoxifen Citrate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Stage II Prostate Adenocarcinoma Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Breast Carcinoma Metastatic in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma Interventions: Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Drug: Veliparib Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Metastatic Cutaneous Melanoma; Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Non-Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage III Mucosal Melanoma of the Head and Neck AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7 Interventions: Biological: Ipilimumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7 Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen Citrate Sponsors: National Cancer Institute (NCI); American College of Surgeons; Cancer and Leukemia Group B; NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group Active, not recruiting
Condition: Multiple Myeloma in Relapse Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc. Recruiting
Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer Interventions: Drug: fulvestrant; Drug: anastrozole Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Active, not recruiting
Condition: Ductal Breast Carcinoma In Situ Interventions: Other: Laboratory Biomarker Analysis; Biological: Trastuzumab; Radiation: Whole Breast Irradiation Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma Interventions: Biological: Bevacizumab; Biological: Ipilimumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer Interventions: Biological: Bevacizumab; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Paclitaxel; Other: Placebo Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; ECOG-ACRIN Cancer Research Group; North Central Cancer Treatment Group Active, not recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Drug: Olaparib Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI); NRG Oncology Recruiting
Condition: Breast Cancer Interventions: Drug: Abemaciclib; Drug: Standard Adjuvant Endocrine Therapy Sponsors: Eli Lilly and Company; NSABP Foundation Inc Active, not recruiting
Conditions: DCIS; Ductal Carcinoma in Situ Interventions: Other: Guideline Concordant Care; Other: Active Surveillance Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; Duke University; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; New York University; Washington University School of Medicine Recruiting
Conditions: Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Tamoxifen Citrate; Drug: Z-Endoxifen Hydrochloride Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Colorectal Cancer Interventions: Biological: cetuximab; Drug: irinotecan hydrochloride; Drug: vemurafenib Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Roche-Genentech Active, not recruiting
Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma Interventions: Drug: Bendamustine Hydrochloride; Drug: Bortezomib; Radiation: Fludeoxyglucose F-18; Other: Laboratory Biomarker Analysis; Biological: Ofatumumab; Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Questionnaire Administration; Drug: Tamoxifen Citrate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Metastatic Breast Cancer Interventions: Drug: Abemaciclib; Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor: Eli Lilly and Company Withdrawn
Condition: Breast Cancer Intervention: Radiation: Radiation Therapy Sponsors: Dana-Farber Cancer Institute; Patient-Centered Outcomes Research Institute Recruiting
Condition: Lung Carcinoma Interventions: Drug: Varenicline; Drug: Placebo; Other: Tobacco Cessation Counseling Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Pfizer Active, not recruiting
Condition: Breast Cancer Interventions: Drug: Palbociclib; Drug: Standard Adjuvant Endocrine Therapy Sponsors: Alliance Foundation Trials, LLC.; Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer Active, not recruiting
Conditions: Diabetes Mellitus, Type 2; Diabetic Nephropathy Interventions: Drug: Canagliflozin; Drug: Placebo Sponsors: Janssen Research & Development, LLC; The George Institute for Global Health, Australia Completed
Conditions: HER2/Neu Positive; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7 Interventions: Drug: Aromatase Inhibition Therapy; Drug: Carboplatin; Other: Cytology Specimen Collection Procedure; Drug: Docetaxel; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Biological: Pertuzumab; Other: Quality-of-Life Assessment; Procedure: Therapeutic Conventional Surgery; Biological: Trastuzumab; Radiation: Whole Breast Irradiation Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Stage IB Breast Cancer; Stage II Breast Cancer Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group Recruiting
Condition: Breast Cancer Interventions: Drug: trastuzumab; Drug: trastuzumab emtansine Sponsors: Hoffmann-La Roche; NSABP Foundation Inc; German Breast Group Active, not recruiting
Conditions: Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction Interventions: Drug: testosterone; Other: placebo Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed
Conditions: Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma Interventions: Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Biological: Rituximab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Coronary Artery Disease; Left Ventricular Dysfunction; Sudden Cardiac Death Intervention: Sponsors: Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); Abbott Medical Devices; Northwestern University; Roche Diagnostics; Quintiles, Inc. Active, not recruiting
Condition: Glioblastoma Multiforme Interventions: Biological: bevacizumab; Drug: dasatinib; Other: placebo Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Completed
Condition: Brain and Central Nervous System Tumors Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group Recruiting
Conditions: Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7 Interventions: Other: Laboratory Biomarker Analysis; Drug: Lapatinib Ditosylate; Drug: Paclitaxel; Biological: Trastuzumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Neoplasms, Breast Interventions: Drug: Lapatinib; Biological: Trastuzumab Sponsors: Novartis Pharmaceuticals; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; Canadian Cancer Trials Group Active, not recruiting
Conditions: Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Fulvestrant; Other: Laboratory Biomarker Analysis; Drug: Lapatinib Ditosylate; Other: Placebo Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer Interventions: Drug: Exemestane; Other: Laboratory Biomarker Analysis; Procedure: Oophorectomy; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen; Drug: Triptorelin Sponsors: International Breast Cancer Study Group; Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group Active, not recruiting
Condition: Breast Cancer Interventions: Drug: tamoxifen citrate; Procedure: adjuvant therapy; Radiation: radiation therapy Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; NRG Oncology Active, not recruiting
Conditions: Other Cancer; Gastrointestinal Cancer; Thoracic Cancer; Gynecologic Cancer Interventions: Other: eSyM App Usage; Other: SASS Questionnaire Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI); RTI International; Baptist Memorial Health Care Corporation; Dartmouth-Hitchcock Medical Center; Maine Medical Center; West Virginia University; Lifespan Recruiting
Condition: Hypertension Interventions: Drug: Hydrochlorothiazide (HCTZ); Drug: Chlorthalidone Sponsor: VA Office of Research and Development Recruiting
Conditions: Breast Carcinoma; Estrogen Receptor Negative; Progesterone Receptor Negative Interventions: Procedure: Screening Mammography; Procedure: Biospecimen Collection Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Condition: Breast Cancer Intervention: Drug: T-DM1 Sponsors: Dana-Farber Cancer Institute; Susan G. Komen Breast Cancer Foundation; Gateway for Cancer Research Recruiting
Condition: Kidney Calculi Intervention: Procedure: Ureteroscopy Sponsors: Vanderbilt University Medical Center; University of Michigan; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Maine Medical Center; Mayo Clinic; Université de Montréal; University of California, Davis; University of California, San Diego; Indiana University Recruiting
Conditions: Atrial Fibrillation; Stroke; Bleeding Interventions: Drug: Antiplatelet-only strategy; Drug: Oral Anticoagulant plus background antiplatelet therapy Sponsors: Icahn School of Medicine at Mount Sinai; National Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical Center Not yet recruiting
Condition: Metastatic Breast Cancer Interventions: Drug: Abemaciclib; Drug: Fulvestrant; Drug: Standard Chemotherapy Sponsor: Eli Lilly and Company Recruiting